Skip to main content

The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]:

Source: Neurology Read More